Dashboard
Manage Tickers

MNKDMANNKIND CORP

Nasdaq mannkindcorp.com


$ 5.19 $ 0.18 (3.59 %)    

Thursday, 08-Aug-2024 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 449.23 $ 13.30 (3.06 %)
DIA $ 395.05 $ 6.75 (1.74 %)
SPY $ 531.28 $ 11.99 (2.31 %)
TLT $ 95.30 $ -0.59 (-0.62 %)
GLD $ 224.00 $ 3.46 (1.57 %)
$ 5.19
$ 5.18 x 700
$ 5.19 x 1,577
-- - --
$ 3.17 - $ 6.04
1,721,003
na
1.42B
$ 1.14
$ 120.73
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-27-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 02-23-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-12-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 02-25-2020 12-31-2019 10-K
20 11-08-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 02-26-2019 12-31-2018 10-K
24 11-01-2018 09-30-2018 10-Q
25 08-02-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 02-27-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 03-15-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 03-02-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

mannkind-q2-2024-adj-eps-005-beats-001-estimate-sales-72386m-beat-64813m-estimate
MannKind Q2 2024 Adj. EPS $0.05 Beats $0.0...
08/07/2024 12:03:21

mannkind-announced-the-launch-of-an-educational-website-designed-to-raise-awareness-of-nontuberculous-mycobacterial-ntm-lung-disease
Mannkind Announced The Launch Of An Educat...
07/31/2024 10:39:34

reported-earlier-mannkinds-inhaled-insulin-afrezza-shows-results-in-17-week-study
Reported Earlier, MannKind's Inhaled Insul...
06/24/2024 07:04:21

 MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products...

rodman--renshaw-initiates-coverage-on-mannkind-with-buy-rating-announces-price-target-of-8
Rodman & Renshaw Initiates Coverage On Man...
06/13/2024 17:42:02

Rodman & Renshaw analyst Brandon Folkes initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Pri...

Core News & Articles
Pulmatrix Enters Cross License Agreement W...
05/29/2024 12:49:00

cantor-fitzgerald-reiterates-overweight-on-mannkind-maintains-65-price-target
Cantor Fitzgerald Reiterates Overweight on...
05/09/2024 14:56:24

Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $6.5 price target.

mannkind-q1-2024-adj-eps-005-beats-003-estimate-sales-66263m-beat-60490m-estimate
MannKind Q1 2024 Adj EPS $0.05 Beats $0.03...
05/08/2024 20:42:59

MannKind (NASDAQ:MNKD) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66....

mannkind-announced-the-fda-fast-track-designation-for-clofazimine-inhalation-suspension-mnkd-101-for-nontuberculous-mycobacterial-lung-disease
MannKind Announced The FDA Fast Track Desi...
05/06/2024 10:10:08

mannkind-will-proceed-with-phase-1-nintedanib-dpi-mnkd-201-study-for-pulmonary-fibrotic-diseases
MannKind Will Proceed With Phase 1 Ninteda...
04/30/2024 10:07:46

mannkind-announces-ind-clearance-from-us-fda-to-start-phase-3-study-of-clofazimine-inhalation-suspension-for-nontuberculous-mycobacterial-ntm-lung-disease
MannKind Announces IND Clearance From US F...
04/29/2024 10:07:05

MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeuti...

mannkind-announced-that-it-has-repaid-in-full-all-outstanding-indebtedness-under-both-its-credit-and-security-agreement-with-midcap-financial-trust-and-its-convertible-promissory-note-issued-to-mann-group-llc
MannKind Announced That It Has Repaid In F...
04/03/2024 10:06:44

Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 million Convertible note is...

mannkind-appoints-christopher-prentiss-as-cfo-effective-april-22-2024-succeeds-steven-binder
MannKind Appoints Christopher Prentiss As ...
03/26/2024 20:07:38

cantor-fitzgerald-reiterates-overweight-on-mannkind-maintains-65-price-target
Cantor Fitzgerald Reiterates Overweight on...
03/15/2024 14:51:51

Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $6.5 price target.

why-mesoblast-shares-are-trading-higher-by-13-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Mesoblast Shares Are Trading Higher By...
03/11/2024 17:41:28

Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an ...

eqt-genie-energy-and-other-big-stocks-moving-lower-on-monday
EQT, Genie Energy And Other Big Stocks Mov...
03/11/2024 14:37:32

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

whats-going-on-with-mannkind-stock
What's Going On With MannKind Stock?
03/11/2024 14:28:31

MannKind Corporation shares are trending on social media Monday. CNBC's Jim Cramer mentioned the stock on the "Mad Mone...

mannkind-announced-initial-meal-challenge-data-from-inhale-3-phase-4-us-trial-comparing-afrezza-head-to-head-with-multiple-daily-injections-and-insulin-pumps
MannKind Announced Initial Meal Challenge ...
03/11/2024 10:13:58

Post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered th...

cramer-says-sprout-social-is-in-a-hot-spot-but-this-energy-stock-is-too-down-and-out
Cramer Says Sprout Social Is In A 'Hot Spo...
03/08/2024 14:13:15

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he needs to do more work on Sprout Social, Inc. (NASDAQ: SPT) ...

mannkind-announced-that-new-clinical-data-from-inhale-3-phase-4-study-of-inhaled-insulin-plus-basal-vs-standard-of-care-at-the-international-conference-on-advanced-technologies-and-treatments-for-diabetes
MannKind Announced That New Clinical Data ...
03/05/2024 11:08:06

cantor-fitzgerald-reiterates-overweight-on-mannkind-maintains-65-price-target
Cantor Fitzgerald Reiterates Overweight on...
02/28/2024 16:22:52

Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $6.5 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION